Association Between Types of Carbapenemase and Clinical Outcomes of Infection Due to Carbapenem Resistance Enterobacterales

References

• van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8(4):460–469. doi:10.1080/21505594.2016.1222343
   PubMed Web of Science ®Google Scholar
• Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18(5):263–272. doi:10.1016/j.molmed.2012.03.003
   PubMed Web of Science ®Google Scholar
• Tilahun M, Kassa Y, Gedefie A, Ashagire M. Emerging carbapenem-resistant Enterobacteriaceae infection, its epidemiology and novel treatment options: a review. Infect Drug Resist. 2021;14:4363–4374. doi:10.2147/IDR.S337611
   PubMed Web of Science ®Google Scholar
• CDC. Clinicians: information about CRE; 2019. Available from: https://www.cdc.gov/hai/organisms/cre/cre-clinicians.html. Accessed June 3, 2022.
   Google Scholar
• Livingstone D, Gill MJ, Wise R. Mechanisms of resistance to the carbapenems. J Antimicrob Chemother. 1995;35(1):1–5. doi:10.1093/jac/35.1.1
   PubMed Web of Science ®Google Scholar
• Ruppé É, Woerther P-L, Barbier F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care. 2015;5(1):61. doi:10.1186/s13613-015-0061-0
   PubMed Web of Science ®Google Scholar
• Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45(4):1151–1161. doi:10.1128/AAC.45.4.1151-1161.2001
   PubMed Web of Science ®Google Scholar
• Temkin E, Adler A, Lerner A, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. Ann N Y Acad Sci. 2014;1323(1):22–42. doi:10.1111/nyas.12537
   Web of Science ®Google Scholar
• Suwantarat N, Carroll KC. Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia. Antimicrob Resist Infect Control. 2016;5(1):15. doi:10.1186/s13756-016-0115-6
   Web of Science ®Google Scholar
• Lunha K, Chanawong A, Lulitanond A, et al. High-level carbapenem-resistant OXA-48-producing Klebsiella pneumoniae with a novel OmpK36 variant and low-level, carbapenem-resistant, non-porin-deficient, OXA-181-producing Escherichia coli from Thailand. Diagn Microbiol Infect Dis. 2016;85(2):221–226. doi:10.1016/j.diagmicrobio.2016.03.009
   Web of Science ®Google Scholar
• Netikul T, Kiratisin P, Nguyen MH. Genetic characterization of carbapenem-resistant Enterobacteriaceae and the spread of carbapenem-resistant Klebsiella pneumonia ST340 at a University Hospital in Thailand. PLoS One. 2015;10(9):e0139116. doi:10.1371/journal.pone.0139116
   Web of Science ®Google Scholar
• Rimrang B, Chanawong A, Lulitanond A, et al. Emergence of NDM-1- and IMP-14a-producing Enterobacteriaceae in Thailand. J Antimicrob Chemother. 2012;67(11):2626–2630. doi:10.1093/jac/dks267
   PubMed Web of Science ®Google Scholar
• Laolerd W, Akeda Y, Preeyanon L, Ratthawongjirakul P, Santanirand P. Carbapenemase-producing carbapenem-resistant Enterobacteriaceae from Bangkok, Thailand, and their detection by the carba NP and modified carbapenem inactivation method tests. Microb Drug Resist. 2018;24(7):1006–1011. doi:10.1089/mdr.2018.0080
   PubMed Web of Science ®Google Scholar
• Paveenkittiporn W, Kamjumphol W, Ungcharoen R, Kerdsin A. Whole-genome sequencing of clinically isolated carbapenem-resistant Enterobacterales harboring mcr genes in Thailand, 2016–2019. Front Microbiol. 2020;11:586368. doi:10.3389/fmicb.2020.586368
   Web of Science ®Google Scholar
• Gharaibeh MH, Shatnawi SQ. An overview of colistin resistance, mobilized colistin resistance genes dissemination, global responses, and the alternatives to colistin: a review. Vet World. 2019;12(11):1735–1746. doi:10.14202/vetworld.2019.1735-1746
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang Y, Yao X, et al. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol Infect Dis. 2016;35(10):1679–1689. doi:10.1007/s10096-016-2710-0
   PubMed Web of Science ®Google Scholar
• Goodman KE, Simner PJ, Tamma PD, Milstone AM. Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE). Expert Rev Anti Infect Ther. 2016;14(1):95–108. doi:10.1586/14787210.2016.1106940
   PubMed Web of Science ®Google Scholar
• Martin A, Fahrbach K, Zhao Q, Lodise T. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis. Open Forum Infect Dis. 2018;5(7):ofy150. doi:10.1093/ofid/ofy150
   PubMed Web of Science ®Google Scholar
• Tamma PD, Goodman KE, Harris AD, et al. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis. 2017;64(3):257–264. doi:10.1093/cid/ciw741
   PubMed Web of Science ®Google Scholar
• Liang Z, Li L, Wang Y, et al. Molecular basis of NDM-1, a new antibiotic resistance determinant. PLoS One. 2011;6(8):e23606. doi:10.1371/journal.pone.0023606
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 2011;66(1):48–53. doi:10.1093/jac/dkq408
   PubMed Web of Science ®Google Scholar
• Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents. 2010;35(3):240–243. doi:10.1016/j.ijantimicag.2009.10.019
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs. 2019;79(3):271–289. doi:10.1007/s40265-019-1055-2
   PubMed Web of Science ®Google Scholar
• Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother. 2012;67(7):1597–1606. doi:10.1093/jac/dks121
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Nine Informational Supplement. Clinical and Laboratory Standards Institute; CLSI document M100. 2020.
   Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. European Antimicrobial Breakpoints. Basel: European Committee on Antimicrobial Susceptibility Testing; 2020.
   Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-3
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Facility guidance for control of Carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update - CRE toolkit; 2015. Available from: https://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf. Accessed June 7, 2022.
   Google Scholar
• Chotiprasitsakul D, Srichatrapimuk S, Kirdlarp S, Pyden AD, Santanirand P. Epidemiology of carbapenem-resistant Enterobacteriaceae: a 5-year experience at a tertiary care hospital. Infect Drug Resist. 2019;12:461–468. doi:10.2147/IDR.S192540
   Web of Science ®Google Scholar
• Ranjan A, Shaik S, Mondal A, et al. Molecular epidemiology and genome dynamics of New Delhi metallo-β-lactamase-producing extraintestinal pathogenic Escherichia coli strains from India. Antimicrob Agents Chemother. 2016;60(11):6795–6805. doi:10.1128/AAC.01345-16
   Web of Science ®Google Scholar
• Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–S36. doi:10.1093/infdis/jiw282
   PubMed Web of Science ®Google Scholar
• Ontong JC, Ozioma NF, Voravuthikunchai SP, Chusri S. Synergistic antibacterial effects of colistin in combination with aminoglycoside, carbapenems, cephalosporins, fluoroquinolones, tetracyclines, fosfomycin, and piperacillin on multidrug resistant Klebsiella pneumoniae isolates. PLoS One. 2021;16(1):e0244673. doi:10.1371/journal.pone.0244673
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–734. doi:10.1016/S1473-3099(17)30228-1
   PubMed Web of Science ®Google Scholar
• Preechachuawong P, Santimaleeworagun W, Jitwasinkul T, Samret W. Detection of New Delhi metallo-beta-lactamase-1-producing Klebsiella pneumoniae at a general hospital in Thailand. Southeast Asian J Trop Med Public Health. 2015;46(6):1031–1036.
   Web of Science ®Google Scholar
• Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–168. doi:10.1016/S1473-3099(15)00424-7
   PubMed Web of Science ®Google Scholar
• Kaye KS, Rice LB, Dane AL, et al. Fosfomycin for injection (ZTI-01) versus Piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a Phase 2/3 randomized trial. Clin Infect Dis. 2019;69(12):2045–2056. doi:10.1093/cid/ciz181
   PubMed Web of Science ®Google Scholar
• American Pharmacists Association. Drug Information Handbook: With International Trade Names Index. 28th ed. Hudson, Ohio: Lexi-Comp; 2019–2020.
   Google Scholar
• American Pharmacists Association. Drug Information Handbook: With International Trade Names Index. 26th ed. Hudson, Ohio: Lexi-Comp; 2017–2018.
   Google Scholar
• Jayol A, Nordmann P, Brink A, Villegas M-V, Dubois V, Poirel L. High-level resistance to colistin mediated by various mutations in the crrB gene among carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61(11):e01423–17. doi:10.1128/AAC.01423-17
   PubMed Web of Science ®Google Scholar
• Olaitan AO, Diene SM, Kempf M, et al. Worldwide emergence of colistin resistance in Klebsiella pneumoniae from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator mgrB: an epidemiological and molecular study. Int J Antimicrob Agents. 2014;44(6):500–507. doi:10.1016/j.ijantimicag.2014.07.020
   PubMed Web of Science ®Google Scholar
• Giani T, Arena F, Vaggelli G, et al. Large nosocomial outbreak of colistin-resistant, Carbapenemase-producing Klebsiella pneumoniae traced to clonal expansion of an mgrB deletion mutant. J Clin Microbiol. 2015;53(10):3341–3344. doi:10.1128/JCM.01017-15
   PubMed Web of Science ®Google Scholar
• Lim FK, Liew YX, Cai Y, et al. Treatment and outcomes of infections caused by diverse carbapenemase-producing Carbapenem-resistant enterobacterales. Front Cell Infect Microbiol. 2020;10:542. doi:10.3389/fcimb.2020.579462
   Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133–2143. doi:10.1093/jac/dkv086
   PubMed Web of Science ®Google Scholar
• Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm DF. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother. 2016;60(8):4743–4749. doi:10.1128/AAC.00220-16
   PubMed Web of Science ®Google Scholar
• Nasomsong W, Nulsopapon P, Changpradub D, et al. The potential use of ceftazidime-avibactam against Carbapenem resistant Klebsiella pneumoniae clinical isolates harboring different carbapenemase types in a Thai University Hospital. Drug Des Devel Ther. 2021;15:3095–3104. doi:10.2147/DDDT.S321147
   PubMed Web of Science ®Google Scholar
• Ko W-C, Stone GG. In vitro activity of ceftazidime–avibactam and comparators against Gram-negative bacterial isolates collected in the Asia–Pacific region as part of the INFORM program (2015–2017). Ann Clin Microbiol Antimicrob. 2020;19(1):14. doi:10.1186/s12941-020-00355-1
   Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169–e83. doi:10.1093/cid/ciaa1478
   PubMed Web of Science ®Google Scholar
• Paveenkittiporn W, Lyman M, Biedron C, et al. Molecular epidemiology of carbapenem-resistant Enterobacterales in Thailand, 2016–2018. Antimicrob Resist Infect Control. 2021;10(1):88. doi:10.1186/s13756-021-00950-7
   PubMed Web of Science ®Google Scholar
• Hansen GT. Continuous evolution: perspective on the epidemiology of carbapenemase resistance among Enterobacterales and other gram-negative bacteria. Infect Dis Ther. 2021;10(1):75–92. doi:10.1007/s40121-020-00395-2
   PubMed Web of Science ®Google Scholar
• Wong D, van Duin D. Novel beta-lactamase inhibitors: unlocking their potential in therapy. Drugs. 2017;77(6):615–628. doi:10.1007/s40265-017-0725-1
   PubMed Web of Science ®Google Scholar
• van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis. 2016;63(2):234–241. doi:10.1093/cid/ciw243
   PubMed Web of Science ®Google Scholar
• Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis. 2017;64(5):565–571. doi:10.1093/cid/ciw839
   PubMed Web of Science ®Google Scholar